Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

Christine Hann, Vincent C. Daniel, Elizabeth Sugar, Irina Dobromilskaya, Sara C. Murphy, Leslie Cope, Xue Lin, Jared S. Hierman, Daniel L. Wilburn, D. Neil Watkins, Charles M. Rudin

Research output: Contribution to journalArticle

Abstract

Bcl-2 is a central regulator of cell survival that is overexpressed in the majority of small cell lung cancers (SCLC) and contributes to both malignant transformation and therapeutic resistance. We compared primary SCLC xenografts prepared from de novo human tumors with standard cell line-based xenografts in the evaluation of a novel and highly potent small molecule inhibitor of Bcl-2, ABT-737. ABT-737 induced dramatic regressions in tumors derived from some SCLC cell lines. In contrast, only one of three primary xenograft SCLC tumors showed significant growth inhibition with ABT-737. Explanations for this apparent dichotomy may include relatively low expression of Bcl-2 in the primary xenografts or inherent differences in the model systems. The addition of etoposide to ABT-737 in the primary xenografts resulted in significant decreases in tumor growth, underscoring the clinical potential of ABT-737 in combination therapy. To identify factors that may contribute to resistance to ABT-737 and related inhibitors, we isolated resistant derivatives of an initially sensitive cell line-based xenograft. Acquired resistance in this model was associated with decreases in the expression of the primary target Bcl-2, of proapoptotic partners of Bcl-2 (Bax and Bim), and of Bcl-2:Bim heterodimers. Expression profiling reveals 85 candidate genes demonstrating consistent changes in gene expression with acquired resistance. Taken together, these data have specific implications for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the testing of novel anticancer strategies in relevant preclinical models.

Original languageEnglish (US)
Pages (from-to)2321-2328
Number of pages8
JournalCancer Research
Volume68
Issue number7
DOIs
StatePublished - Apr 1 2008

Fingerprint

Small Cell Lung Carcinoma
Heterografts
Cell Line
Neoplasms
Therapeutics
Etoposide
Growth
ABT-737
Cell Survival
Gene Expression
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. / Hann, Christine; Daniel, Vincent C.; Sugar, Elizabeth; Dobromilskaya, Irina; Murphy, Sara C.; Cope, Leslie; Lin, Xue; Hierman, Jared S.; Wilburn, Daniel L.; Watkins, D. Neil; Rudin, Charles M.

In: Cancer Research, Vol. 68, No. 7, 01.04.2008, p. 2321-2328.

Research output: Contribution to journalArticle

Hann, C, Daniel, VC, Sugar, E, Dobromilskaya, I, Murphy, SC, Cope, L, Lin, X, Hierman, JS, Wilburn, DL, Watkins, DN & Rudin, CM 2008, 'Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer', Cancer Research, vol. 68, no. 7, pp. 2321-2328. https://doi.org/10.1158/0008-5472.CAN-07-5031
Hann, Christine ; Daniel, Vincent C. ; Sugar, Elizabeth ; Dobromilskaya, Irina ; Murphy, Sara C. ; Cope, Leslie ; Lin, Xue ; Hierman, Jared S. ; Wilburn, Daniel L. ; Watkins, D. Neil ; Rudin, Charles M. / Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. In: Cancer Research. 2008 ; Vol. 68, No. 7. pp. 2321-2328.
@article{0449504feb50416c9c0ed846911d9a5a,
title = "Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer",
abstract = "Bcl-2 is a central regulator of cell survival that is overexpressed in the majority of small cell lung cancers (SCLC) and contributes to both malignant transformation and therapeutic resistance. We compared primary SCLC xenografts prepared from de novo human tumors with standard cell line-based xenografts in the evaluation of a novel and highly potent small molecule inhibitor of Bcl-2, ABT-737. ABT-737 induced dramatic regressions in tumors derived from some SCLC cell lines. In contrast, only one of three primary xenograft SCLC tumors showed significant growth inhibition with ABT-737. Explanations for this apparent dichotomy may include relatively low expression of Bcl-2 in the primary xenografts or inherent differences in the model systems. The addition of etoposide to ABT-737 in the primary xenografts resulted in significant decreases in tumor growth, underscoring the clinical potential of ABT-737 in combination therapy. To identify factors that may contribute to resistance to ABT-737 and related inhibitors, we isolated resistant derivatives of an initially sensitive cell line-based xenograft. Acquired resistance in this model was associated with decreases in the expression of the primary target Bcl-2, of proapoptotic partners of Bcl-2 (Bax and Bim), and of Bcl-2:Bim heterodimers. Expression profiling reveals 85 candidate genes demonstrating consistent changes in gene expression with acquired resistance. Taken together, these data have specific implications for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the testing of novel anticancer strategies in relevant preclinical models.",
author = "Christine Hann and Daniel, {Vincent C.} and Elizabeth Sugar and Irina Dobromilskaya and Murphy, {Sara C.} and Leslie Cope and Xue Lin and Hierman, {Jared S.} and Wilburn, {Daniel L.} and Watkins, {D. Neil} and Rudin, {Charles M.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-07-5031",
language = "English (US)",
volume = "68",
pages = "2321--2328",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

AU - Hann, Christine

AU - Daniel, Vincent C.

AU - Sugar, Elizabeth

AU - Dobromilskaya, Irina

AU - Murphy, Sara C.

AU - Cope, Leslie

AU - Lin, Xue

AU - Hierman, Jared S.

AU - Wilburn, Daniel L.

AU - Watkins, D. Neil

AU - Rudin, Charles M.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Bcl-2 is a central regulator of cell survival that is overexpressed in the majority of small cell lung cancers (SCLC) and contributes to both malignant transformation and therapeutic resistance. We compared primary SCLC xenografts prepared from de novo human tumors with standard cell line-based xenografts in the evaluation of a novel and highly potent small molecule inhibitor of Bcl-2, ABT-737. ABT-737 induced dramatic regressions in tumors derived from some SCLC cell lines. In contrast, only one of three primary xenograft SCLC tumors showed significant growth inhibition with ABT-737. Explanations for this apparent dichotomy may include relatively low expression of Bcl-2 in the primary xenografts or inherent differences in the model systems. The addition of etoposide to ABT-737 in the primary xenografts resulted in significant decreases in tumor growth, underscoring the clinical potential of ABT-737 in combination therapy. To identify factors that may contribute to resistance to ABT-737 and related inhibitors, we isolated resistant derivatives of an initially sensitive cell line-based xenograft. Acquired resistance in this model was associated with decreases in the expression of the primary target Bcl-2, of proapoptotic partners of Bcl-2 (Bax and Bim), and of Bcl-2:Bim heterodimers. Expression profiling reveals 85 candidate genes demonstrating consistent changes in gene expression with acquired resistance. Taken together, these data have specific implications for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the testing of novel anticancer strategies in relevant preclinical models.

AB - Bcl-2 is a central regulator of cell survival that is overexpressed in the majority of small cell lung cancers (SCLC) and contributes to both malignant transformation and therapeutic resistance. We compared primary SCLC xenografts prepared from de novo human tumors with standard cell line-based xenografts in the evaluation of a novel and highly potent small molecule inhibitor of Bcl-2, ABT-737. ABT-737 induced dramatic regressions in tumors derived from some SCLC cell lines. In contrast, only one of three primary xenograft SCLC tumors showed significant growth inhibition with ABT-737. Explanations for this apparent dichotomy may include relatively low expression of Bcl-2 in the primary xenografts or inherent differences in the model systems. The addition of etoposide to ABT-737 in the primary xenografts resulted in significant decreases in tumor growth, underscoring the clinical potential of ABT-737 in combination therapy. To identify factors that may contribute to resistance to ABT-737 and related inhibitors, we isolated resistant derivatives of an initially sensitive cell line-based xenograft. Acquired resistance in this model was associated with decreases in the expression of the primary target Bcl-2, of proapoptotic partners of Bcl-2 (Bax and Bim), and of Bcl-2:Bim heterodimers. Expression profiling reveals 85 candidate genes demonstrating consistent changes in gene expression with acquired resistance. Taken together, these data have specific implications for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the testing of novel anticancer strategies in relevant preclinical models.

UR - http://www.scopus.com/inward/record.url?scp=42049104916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049104916&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-5031

DO - 10.1158/0008-5472.CAN-07-5031

M3 - Article

C2 - 18381439

AN - SCOPUS:42049104916

VL - 68

SP - 2321

EP - 2328

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -